Board Member
Amylyx Pharmaceuticals, Inc. (AMLX)Equibles does not estimate personal net worth.
Get an email with a short summary when Amylyx Pharmaceuticals, Inc. publishes a filing, an earnings call transcript or a press release.
Get AMLX alertsJoshua Cohen is recorded as Board Member at Amylyx Pharmaceuticals, Inc. (AMLX) since January 1, 2014 and CEO at Amylyx Pharmaceuticals, Inc. (AMLX). The newest filing on record that lists Joshua Cohen as CEO and Board Member at Amylyx Pharmaceuticals, Inc. (AMLX) is dated April 23, 2026. The proxy statement of Amylyx Pharmaceuticals, Inc. reports total compensation of $2,719,807 for Joshua Cohen in fiscal 2025, including a base salary of $686,200. Disclosed compensation is on record for 6 fiscal years. Joshua Cohen has spoken on 9 earnings calls and 2 other investor events across 1 company, most recently for Amylyx Pharmaceuticals, Inc. on September 15, 2026. Amylyx Pharmaceuticals, Inc. is classified in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. Other leadership on record at Amylyx Pharmaceuticals, Inc. includes Justin Klee (CEO and Board Member), James Frates (CFO), Gina M. Mazzariello (General Counsel) and 2 others.
“Sure, yeah, so first I'd say we had high expectations given all of the prior trials of the vexatide, but I'd say this exceeded our expectations. The data, just to kind of highlight our pre-specified primary outcome, which was the rate of level 2 and level 3 hypoglycemia in people living with PBH.”
“So we're very excited about the phase three readout expected next quarter. Avexatide, our lead asset, has been through five prior trials, all of which showed highly statistically significant effects on glucose and insulin.”
“To close, we are focused on the execution of the LUCIDITY trial as we track toward our anticipated top line readout next quarter. PBH is a chronic lifelong condition with symptoms that often emerge 1 to 3 years following bariatric surgery.”
“While our immediate focus is on Avexatide, our broader pipeline strategy is designed to leverage our expertise in endocrine conditions and neurodegenerative diseases to build a diverse portfolio of potential medicines.”
“Our conviction in inhibiting the GLP-1 receptor as a therapeutic approach remains strong. While LUCIDITY remains our primary focus, we also view it as a starting point, both for avexitide and for advancing research into GLP-1 receptor antagonism more broadly.”
2014-01-01–present
Last confirmed April 23, 2026
Start not stated–present
Last confirmed April 23, 2026
Drug Manufacturers - Specialty & Generic · Healthcare
CEO, Board Member
2014-01-01–present
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Amylyx Pharmaceuticals, Inc. (AMLX) | Co-Chief Executive Officer and Director | $686,200 | $2,719,807 |
| 2024 | Amylyx Pharmaceuticals, Inc. (AMLX) | Co-Chief Executive Officer and Director | $686,200 | $6,496,255 |
| 2023 | Amylyx Pharmaceuticals, Inc. (AMLX) | Co-Chief Executive Officer and Director | $621,000 | $7,418,169 |
| 2022 | Amylyx Pharmaceuticals, Inc. (AMLX) | Co-Chief Executive Officer and Director | $539,275 | $7,178,416 |
| 2021 | Amylyx Pharmaceuticals, Inc. (AMLX) | Co-Chief Executive Officer and Director | $417,833 | $1,424,533 |
| 2020 | Amylyx Pharmaceuticals, Inc. (AMLX) | Co-Chief Executive officer and Director | $370,000 | $670,500 |
